Furthermore, serplulimab, in combination with other chemotherapeutic agents, significantly enhanced PFS and OS in previously untreated PD-L1 positive advanced ESCC patients while maintaining a manageable safety profile [180]. This evidence concerns the gene CD274 and esophageal squamous cell carcinoma.